Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study

Journal for immunotherapy of cancer - 1 Jun 2020

Bai Xue, Wu De-Hua, Ma Si-Cong, Wang Jian, Tang Xin-Ran, Kang Shuai, Fu Qiang John, Cao Chuan-Hui, Luo He-San, Chen Yu-Han, Zhu Hong-Bo, Yan Hong-Hong, Wu Yi-Long, Dong Zhong-Yi

Abstract excerpt

BACKGROUND: Genetic variations of some driver genes in non-small cell lung cancer (NSCLC) had shown potential impact on immune microenvironment and associated with response or resistance to programmed cell death protein 1 (PD-1) blockade immunotherapy. We therefore undertook an exploratory analysis to develop a genomic mutation signature (GMS) and predict the response to anti-PD-(L)1 therapy. METHODS: In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genomics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 32606052
DOI: 10.1136/jitc-2019-000381
PMCID: PMC7328897

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort studyPMID 32606052Read ↗

Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC.Semantic proximity Read ↗

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung CancerSemantic proximity Read ↗

Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction.Semantic proximity Read ↗

Association Between Tumor Mutation Burden (TMB) and immune microenvironment in lung squamous cell carcinomaSemantic proximity Read ↗

Analyses of multi-omics differences between patients with high and low PD1/PDL1 expression in lung squamous cell carcinoma.Semantic proximity Read ↗

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.Semantic proximity Read ↗

Multidimensional characterization of the tumor microenvironment profiles in lung squamous cell carcinoma.Semantic proximity Read ↗

Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohortSemantic proximity Read ↗

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.Semantic proximity Read ↗

Mutation mapping of PD-L1 expression in advanced non-small cell lung cancer: A real-world retrospective cohort studySemantic proximity Read ↗

Non-driver somatic alteration burden confers good prognosis in non-small cell lung cancerSemantic proximity Read ↗

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.